Bonard
Franck Bonard, Santa Clara, CA US
Patent application number | Description | Published |
---|---|---|
20160086617 | SYSTEM AND METHOD FOR ADDRESSING DISCONTINUOUS TRANSMISSION IN A NETWORK DEVICE - Embodiments included herein are directed towards a system and method for addressing discontinuous transmission (DTX) in a network device. Embodiments may include receiving, at a computing device, an audio signal and generating at least one silence descriptor (SID) frame associated with the audio signal. Embodiments may also include generating at least one no data frame associated with the audio signal. Embodiments may also include initiating a speech decoder, voice enhancement, and speech encoder operation for the at least one SID frame during a DTX operation and bypassing the speech decoder, voice enhancement, and speech encoder functions for the at least one no data frame. | 03-24-2016 |
Jean-Marc Bonard, Lausanne CH
Patent application number | Description | Published |
---|---|---|
20150023140 | INTEGRAL ASSEMBLY OF A HAIRSPRING AND A COLLET - An integral assembly of a single or double hairspring and an unsplit collet including two portions opposite one another for receiving the balance staff, one portion including one of the bearing surfaces ( | 01-22-2015 |
Jean-Michel Bonard, Villeurbanne FR
Patent application number | Description | Published |
---|---|---|
20090023775 | 1-[2-(4-BENZYL-4-HYDROXY-PIPERIDIN-1 -YL )-ETHYL]-3-(2-METHYL-QUINOLIN- 4-YL)- UREA AS CRYSTALLINE SULFATE SALT - The invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt alone or in combination with other compounds. Further, the present invention relates to formulations of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline, stoichiometrically defined and non-hygroscopic sulfate salt in the preparation of pharmaceutical compositions. The invention also relates to the use of such sulfate salts in formulations as neurohormonal antagonists. | 01-22-2009 |